WO2006131326A2 - Novel use of (-)-epigallocatechin gallate - Google Patents
Novel use of (-)-epigallocatechin gallate Download PDFInfo
- Publication number
- WO2006131326A2 WO2006131326A2 PCT/EP2006/005410 EP2006005410W WO2006131326A2 WO 2006131326 A2 WO2006131326 A2 WO 2006131326A2 EP 2006005410 W EP2006005410 W EP 2006005410W WO 2006131326 A2 WO2006131326 A2 WO 2006131326A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- humans
- body weight
- epigallocatechin gallate
- group
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention refers to the use of (-)-epigallocatechin gallate (EGCG), preferably in combination with a sympathomimeticum, - for increasing/stimulating the fat oxidation in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans, especially during post prandial conditions;
- EGCG epigallocatechin gallate
- mammals selected from the group consisting of hu- mans, cats, dogs and horses, preferably in humans;
- the preferred sympathomimeticum is caffeine.
- the invention further refers to the corre- sponding methods. Uses
- a first object of the present invention is the use of EGCG for increasing the fat oxidation in mammals selected from the group consisting of humans, cats, dogs and horses, prefera- bly in humans.
- EGCG has especially an influence on the prandial and post-prandial fat oxidation.
- the EGCG may be administered in the form of (fortified) food or (fortified) feed, dietary supplements, beverages, tablets, granules, capsules, pastes, food additives, feed additives, or effervescent formulations. If it is administered in the form of a beverage, it shows its positive influence on the fat oxidation faster than if it is administered in the form of a capsule. In a preferred embodiment of the present invention EGCG is therefore administered in such a way that it is present or moreover that its concentration is at a high level during the intake of food/feed/beverages, especially during the fat intake, of the mammal. That means that EGCG is preferably administered before or simultaneously with the food/feed/beverages.
- the EGCG is part of the food/feed.
- Examples are cereal bars containing EGCG.
- EGCG is used in combination with a sympathomimeticum.
- Espe- cially preferred is also the use of compositions such as dietary supplements consisting essentially of EGCG and caffeine.
- the energy expenditure is not changed by the increased fat oxidation induced by the use of EGCG.
- a second object of the present invention is the use of EGCG for supporting the metaboli- zation of fat in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans.
- EGCG is therefore administered in such a way that it is present or moreover that its concentration is at a high level during the intake of food/feed/beverages, especially during the fat intake, of the mammal selected from the group consisting of humans, cats, dogs and horses, preferably of the humans. That means that EGCG is preferably administered before or simultaneously with the food/feed/beverages.
- the EGCG is part of the food/feed. Examples are cereal bars containing EGCG.
- a third object of the present invention is the use of EGCG for reducing the weight of mammals selected from the group consisting of humans, cats, dogs and horses, preferably the weight of humans.
- EGCG is used in combination with a sympathomimeticum.
- a forth object of the present invention is the use of EGCG for reducing the fat mass in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans.
- EGCG is used in combination with a sympathomimeticum.
- the visceral and/or the subcutaneous fat is reduced by the use of EGCG, preferably in combination with a sympathomimeticum.
- the visceral fat layer is considered an important element in the development of the metabolic syndrome.
- a fifth object of the present invention is the use of EGCG, preferably in combination with a sympathomimeticum, for increasing the endurance in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans. Therefore, the present invention is also directed to sport beverages containing EGCG, preferably highly purified EGCG as defined below, more preferably in combination with caffeine.
- a sixth object of the present invention is the use of EGCG for reducing the carbohydrate oxidation in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans.
- EGCG is used in combination with a sympathomimeticum.
- a seventh object of the present invention is the use of EGCG for reducing the respiratory quotient in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans.
- EGCG is used in combination with a sympathomimeticum.
- Respiratory quotient CRO Animal cells obtain energy in the form of ATP by oxidizing food molecules through the process of respiration. Carbohydrates and fatty acids are the most important fuels for generating ATP in animal cells. - A -
- the respiratory quotient measures the ratio of the volume of carbon dioxide (V(Co 2 )) produced by an organism to the volume of oxygen consumed (V(O 2 )).
- the volumes of O 2 and CO 2 are measured by indirect calorimetry
- An eighth object of the present invention is the use of EGCG for improving the flow mediated dilation, thereby contributing to the beneficial effects on coronary health, in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans.
- EGCG acutely increases the flow mediated dilation thereby improving the endothelial function.
- EGCG elicits this effect when present in plasma.
- Endothelial function is regarded as an important element in the development of the metabolic syndrome. Thus, EGCG prevents the development of the metabolic syndrome.
- the used EGCG has a purity of at least 80%, preferably of at least 85%, more preferably of at least 90%, even more preferably of at least 92%, most preferably of at least 94%.
- an aqueous green tea extract containing EGCG in an amount of at least 80% (preferred of at least 85%, more preferred of at least 90%, even more preferred of at least 92%, most preferred of at least 94%), based on the total amount of the extract, as e.g. and preferably obtained by any of the processes described in US 6,383,392, EP 1 103 550, US 10/246 112 and EP 1 077 21 1.
- the total amount of other polyphenols and catechins such as gallocatechin gallate, catechin gallate, epicatechin gallate, epigallocatechin, gallocatechin and epicate- chin is low, preferably it is ⁇ 5 weight-%, based on the total weight of the green tea extract. More preferably the amount of gallocatechin gallate is ⁇ 2.5 weight-%, and/or the amount of epicatechin gallate is ⁇ 5 weight-% (preferably ⁇ 3 weight-%), and/or the amount of caffeine is ⁇ 2.5 weight-%, preferably ⁇ 0.1 weight-%, and/or the amount of gallic acid is ⁇ 0.1 weight-%, based on the total weight of the green tea extract.
- a sympathomimeticum is a substance that stimulates the sympathetic nervous system.
- a preferred example of such a substance is caffeine. Therefore the present invention refers to the use of a combination of EGCG and caffeine for the uses as given above. If caffeine is used in combination with EGCG the daily dosage of caffeine varies preferably from 2.5 mg per kg body weight to 7.5 mg per kg body weight.
- sympathomimetica that may be used in combination with EGCG are theophylline, theobromine or extracts of xanthine containing plants such as cacao plants, coffee plants, barley and ginger.
- the sympathetic nervous system is also stimulated by physical activity such as sport, so that sport can also be seen as sympathomimeticum. Therefore, the present invention relates also to the use of EGCG as given above, preferably of highly purified EGCG as defined above, in combination with physical activity.
- Preferred subjects for the uses/methods of the present invention are humans.
- the daily dosage of EGCG varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most preferably from 4.0 to 4.5 mg per kg body weight per day.
- the daily dosage of EGCG varies from 10 to 1500 mg, preferably from 150 to 600 mg, more preferably from 300 to 600 mg, most preferably it is 300 mg.
- a ninth object of the present invention is a method for increasing the fat oxidation in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans, said method comprising the step of administering an effective dose of EGCG, preferably in combination with an effective dose of a sympathomimeticum, to a mammal selected from the group consisting of humans, cats, dogs and horses, preferably to a human, which is in need thereof, characterized in that the effective dose of (-)- epigallocatechin gallate varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most preferably from 4.0 to 4.5 mg per kg body weight per day.
- a tenth object of the present invention is a method for supporting the metabolization of fat in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans, said method comprising the step of administering an effective dose of EGCG, preferably in combination with an effective dose of a sympathomimeticum, to a mammal selected from the group consisting of humans, cats, dogs and horses, preferably to a human, which is in need thereof, characterized in that the effective dose of (-)- epigallocatechin gallate varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most preferably from 4.0 to 4.5 mg per kg body weight per day.
- An eleventh object of the present invention is a method for reducing the fat mass in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans, said method comprising the step of administering an effective dose of EGCG, preferably in combination with a sympathomimeticum, to a mammal selected from the group consisting of humans, cats, dogs and horses, preferably to a human, which is in need thereof, characterized in that the effective dose of EGCG varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most preferably from 4.0 to 4.5 mg per kg body weight per day.
- a twelfth object of the present invention is a method for reducing the weight of mammals selected from the group consisting of humans, cats, dogs and horses, preferably for reducing the weight of humans, said method comprising the step of administering an effective dose of EGCG, preferably in combination with a sympathomimeticum, to a mammal selected from the group consisting of humans, cats, dogs and horses, preferably to a human, which is in need thereof, characterized in that the effective dose of EGCG varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most preferably from 4.0 to 4.5 mg per kg body weight per day.
- a thirteenth object of the present invention is a method for increasing the endurance in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans, said method comprising the step of administering an effective dose of EGCG, preferably in combination with a sympathomimeticum, to a mammal selected from the group consisting of humans, cats, dogs and horses, preferably to a human, which is in need thereof, characterized in that the effective dose of EGCG varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most preferably from 4.0 to 4.5 mg per kg body weight per day.
- a forteenth object of the present invention is a method for reducing the carbohydrate oxi- dation in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans, said method comprising the step of administering an effective dose of EGCG, preferably in combination with a sympathomimeticum, to a mammal selected from the group consisting of humans, cats, dogs and horses, preferably to a human, which is in need thereof, characterized in that the effective dose of EGCG varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most preferably from 4.0 to 4.5 mg per kg body weight per day.
- the methods further comprise the step of the mammals selected from the group consisting of humans, cats, dogs and horses performing physical activity, preferably the methods further comprise the step of the humans performing physical activity.
- a fifteenth object of the present invention is a method for reducing the respiratory quotient in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans, said method comprising the step of administering an effective dose of (-)- epigallocatechin gallate, preferably in combination with a sympathomimeticum, to a mammal selected from the group consisting of humans, cats, dogs and horses, preferably to a human, which is in need thereof, characterized in that the effective dose of (-)-epigallo- catechin gallate varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most preferably from 4.0 to 4.5 mg per kg body weight per day.
- a sixteenth object of the present invention is a method for improving the flow mediated dilation in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans, thereby contributing to a beneficial effect on the coronary health, said method comprising the step of administering an effective dose of (-)-epigallocatechin gallate to a mammal selected from the group consisting of humans, cats, dogs and horses, preferably to a human, which is in need thereof, characterized in that the effective dose of (-)-epigallocatechin gallate varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most preferably from 4.0 to 4.5 mg per kg body weight per day.
- the mammals are humans with a body mass index above 25.
- the body mass index is the number obtained by dividing the body weight in kilogramm of a human by the square of its height in meters.
- the EGCG has a purity of at least 80%, preferably of at least 85%, more preferably of at least 90%, even more preferably of at least 92%, most preferably of at least 94%.
- an EGCG obtained by any of the processes described in US 6,383,392, EP 1 103 550, US 10/246 112 and EP 1 077 211.
- the EGCG may be administered in the form of (fortified) food or (fortified) feed, dietary supplements, beverages, food additives, or feed additives.
- Non-limiting examples of food are dairy products such as yoghurts, cereal bars and bakery items such as cakes and cookies; but EGCG may also be added to any other food/feed a mammal selected from the group consisting of humans, cats, dogs and horses regularly eats. Food may also be in liquid form such as soups and dairy products (muesli drinks).
- Non-limiting examples of beverages for humans are non-alcoholic drinks such as soft drinks, sport drinks, fruit juices, lemonades, near-water drinks (i.e. low calorie drinks based on water), teas and milk based drinks.
- Preferred forms of dietary supplements are tablets, pills, granules, dragees, capsules, and effervescent formulations.
- EGCG is administered in the form of a beverage, it shows its positive influence on the fat oxidation and the endurance faster than if it is administered in the form of a capsule.
- EGCG is therefore administered in such a way that it is present or moreover that its concentration is at a high level during the intake of food/feed/beverages, especially during the fat intake, of the mammal selected from the group consisting of humans, cats, dogs and horses, preferably of the human, and during the activity for which endurance is needed, respectively. That means that EGCG is preferably administered before or simultaneously with the food/feed/beverages.
- the (composition/dietary supplement containing) EGCG is incorporated by the mammal selected from the group consisting of humans, cats, dogs and horses, preferably of the human, at least half an hour before the intake of food, feed or beverages, preferably at a point in time between 0.5 and 1.5 hours before the intake of food, feed or beverages. If EGCG is administered in form of fortified food, feed or beverages it is simultaneously incorporated by the mammal selected from the group consisting of humans, cats, dogs and horses, preferably of the human, with such fortified food, feed or beverage.
- EGCG is used in combination with a sympathomimeticum.
- the present invention is also directed to the use of (-)-epigallocatechin gallate, preferably in combination with a sympathomimeticum, for the manufacture of a composition - for increasing the fat oxidation in mammals selected from the group consisting of humans, cats, dogs and horses, preferably in humans;*
- composition is administered in such a way that (-)-epigallocatechin gallate is present in the body during the intake of food/feed/beverages of the mammal, preferably that it is present in a high concentration in the body during the intake of food/feed/beverages of the mammal selected from the group consisting of humans, cats, dogs and horses, preferably of the human.
- composition is administered in such a way that (-)-epigallocatechin gallate is present, preferably in high concentration, in the body when the mammal selected from the group consisting of humans, cats, dogs and horses, preferably when the human, is performing the activity for which endurance is needed.
- the dietary supplement is incorporated by said mammal at least half an hour before the intake of food, feed or beverages, even more pre- ferred at a point in time between half an hour and one and a half hour before the intake of food, feed or beverages.
- the EGCG has a purity of at least 80%, preferably of at least 85%, more preferably of at least 90%, even more preferably of at least 92%, most preferably of at least 94%.
- an aqueous green tea extract containing EGCG in an amount of at least 80% (preferred of at least 85%, more preferred of at least 90%, even more preferred of at least 92%, most preferred of at least 94%), based on the total amount of the extract, as e.g. and preferably obtained by any of the processes described in US 6,383,392, EP 1 103 550, US 10/246 112 and EP 1 077 211.
- the total amount of other polyphenols and catechins such as gallocatechin gallate, catechin gallate, epicatechin gallate, epigallocatechin, gallocatechin and epicatechin is low, preferably it is ⁇ 5 weight-%, based on the total weight of the green tea extract. More preferably the amount of gallocatechin gallate is ⁇ 2.5 weight-%, and/or the amount of epicatechin gallate is ⁇ 5 weight-% (preferably ⁇ 3 weight-%), and/or the amount of caffeine is ⁇ 2.5 weight-%, preferably ⁇ 0.1 weight-%, and/or the amount of gallic acid is ⁇ 0.1 weight-%, based on the total weight of the green tea extract.
- the dietary supplement preferably additionally contains a sympathomimeticum such as caffeine. Therefore the present invention refers to the use of a combination of EGCG and caffeine for the uses as given above. If caffeine is used in combination with EGCG the daily dosage of caffeine varies preferably from 2.5 mg per kg body weight to 7.5 mg per kg body weight.
- the sympathetic nervous system is also stimulated by physical activity such as sport, so that sport can also be seen as sympathomimeticum. Therefore, the present invention relates also to the use of EGCG as given above, preferably of highly purified EGCG as defined above, in combination with physical activity.
- Preferred subjects for the uses/methods of the present invention are humans.
- the daily dosage of EGCG varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most pref- erably from 4.0 to 4.5 mg per kg body weight per day.
- the daily dosage of EGCG varies from 10 to 1500 mg, preferably from 150 to 600 mg, more preferably from 300 to 600 mg, most preferably it is 300 mg.
- the dietary supplement containing (-)-epigallocatechin gallate may be incorporated by the mammal simultaneously with the food, feed or beverage, respectively.
- further objects of the present invention are: 0 Use of a dietary supplement containing (-)-epigallocatechin gallate for increasing the fat oxidation in mammals selected from the group consisting of humans, cats, dogs and horses, whereby the dietary supplement is incorporated by said mammal simultaneously with the regular intake of food, feed or beverages containing said fat whose oxidation is increased.
- a dietary supplement containing (— )-epigallocatechin gallate for reducing the weight of a mammal selected from the group consisting of humans, cats, dogs and horses, whereby the dietary supplement is incorporated by said mammal simultaneously with the intake of food, feed or beverages.
- a dietary supplement containing (-)-epigallocatechin gallate for reducing the fat mass in mammals selected from the group consisting of humans, cats, dogs and horses, whereby the dietary supplement is incorporated by said mammal simultaneously with the intake of food, feed or beverages.
- a dietary supplement containing (-)-epigallocatechin gallate for reducing the carbohydrate oxidation in mammals selected from the group consisting of humans, cats, dogs and horses, whereby the dietary supplement is incorporated by said mammal simultane- ously with the regular intake of food, feed or beverages containing said carbohydrate whose oxidation is reduced.
- the food, feed or beverage itself may be fortified with (-)-epigallocatechin gallate.
- (-)-epigallocatechin gallate is incorporated by said mammal simultaneously with the intake of food, feed and beverages, respectively.
- the food, feed or beverage is fortified with EGCG in such an amount so that the daily dosage of EGCG varies from 0.14 to 25 mg per kg body weight per day, preferably from 2.0 to 9 mg per kg body weight per day, more preferably from 4.0 to 9.0 mg per kg body weight per day, most preferably from 4.0 to 4.5 mg per kg body weight per day.
- the food, feed or beverage is fortified with EGCG in such an amount so that the daily dosage of EGCG varies from 10 to 1500 mg, preferably from 150 to 600 mg, more preferably from 300 to 600 mg, most preferably it is 300 mg.
- Experiment D 150 mg EGCG + 100 mg caffeine, one capsule, twice per day per os for two days;
- Experiment E placebo, one capsule, twice per day per os for two days; two capsules, prior basal and one capsule prior to post-prandial measurement.
- the study supplements were taken orally twice daily, 1.0 hours before breakfast and dinner, respectively for which specific nutritional guidelines had to be followed.
- variable was treatment (EGCG, caffeine, placebo). Pairwise comparison across treatments was per- formed by using t-test with bonferroni's correction. A p- value smaller than 0.05 was considered significant. Values are given as mean ⁇ SD. Graphical displays were generated. If a numeric and/or statistical analysis was not possible a descriptive analysis was done.
- the "*" indicates a statistical significance between treatment and placebo, whereas "p” represents the probability that an observed difference between the intervention and control groups is due to chance alone if the null hypothesis is true.
- a p- value of 0.05 or less rejects the null hypothesis "at the 5% level", i.e. the statistical assumptions used imply that only 5% of the time the supposed statistical process would pro- prise a finding this extreme that the null hypothesis is true.
- 5% and 10% are common significance levels to which p-values are compared.
- Fig. 1 shows the difference in the respiratory quotient of the groups A to D in comparison to group E.
- the respiratory quotient was assessed by indirect calorimetry using a Deltatrac.
- group A, C and D the respiratory quotient was reduced in comparison to group E during basal conditions.
- these differences were still existing or even increased.
- the respiratory quotient was also different between group B and group E.
- Fig. 2 shows the difference in the lipid oxidation rate of the groups A to D in comparison to group E.
- the lipid oxidation rate was assessed by indirect calorimetry using a Deltatrac.
- group A, B, C and D the lipid oxidation rate was increased in comparison to group E during basal conditions. During post prandial conditions these differences were more pronounced.
- Statistical significance was observed for group C and D during basal conditions and for group D at post prandial conditions.
- Fig. 3 shows the difference in the carbohydrate oxidation rate of the groups A to D in comparison to group E.
- the carbohydrate oxidation rate was assessed by indirect calorimetry using a Deltatrac.
- group A, B, C and D the carbohydrate oxidation rate was reduced in comparison to group E during basal conditions. During post prandial conditions these differences were more pronounced. Statistical significance was observed for group D during prandial conditions.
- Fig. 4 shows the increase in the lipid oxidation rate of the groups A to D relative to group E between basal and post prandial conditions.
- the lipid oxidation rate was assessed by indirect calorimetry using a Deltatrac. There was an increase in lipid oxidation rate from basal to post prandial conditions in group A, B, and C, whereas it was highest in group A. No change was observed for group D.
- Fig. 5 shows the lipid oxidation rate of the groups A, C, D and E during maximum post prandial stimulation due to the test meal.
- the lipid oxidation rate was assessed by indirect calorimetry using a Deltatrac. Lipid oxidation rate increased in group A, C, D, and E, whereas the lipid oxidation rate of group A, C and D were higher compared to group E,
- Fig. 6 shows the synergism between groups A and C on fat oxidation during maximum post prandial stimulation.
- the lipid oxidation rate was assessed by indirect calorimetry using a Deltatrac.
- Group D has higher lipid oxidation than the sum of group A and group C, suggesting a synergism.
- FIG. 8 TEAVIGOTM improves flow mediated dilation
- Fig. 8 shows the difference in flow mediated dilation (FMD) of the groups A and E in comparison to baseline for acute (2 hours), and chronic (2 weeks) treatment.
- FMD flow mediated dilation
- Fig. 9 shows the difference in EGCG plasma levels the groups A and E in comparison to baseline for acute (2 hours), and chronic (2 weeks) treatment.
- EGCG in plasma was determined by High Performance Liquid Chromatography-Mass Spectrometry.
- group A EGCG levels were increased after acute administration.
- group E after acute administration.
- group E after chronic treatment.
- the plasma EGCG level returned to baseline after chronic treatment. This is due to assessing the EGCG level 14 hours after the last administration. Therefore, EGCG does not accumulate in plasma.
- Fig. 10 shows the lipid oxidation rate of the groups A to E.
- the lipid oxidation rate was assessed by indirect calorimetry using a Deltatrac. In all groups the lipid oxidation rate is higher during basal conditions compared to post prandial conditions. Between groups, lipid oxidation rate in group E is lowest under the respective condition. Statistical significance was observed for group C and D during basal conditions and for group D at post prandial conditions.
- Fig. 11 shows the carbohydrate oxidation rate of the groups A to E.
- the carbohydrate oxidation rate was assessed by indirect calorimetry using a Deltatrac. In all groups the carbo- hydrate oxidation rate is higher during post prandial conditions compared to basal conditions. Between groups, carbohydrate oxidation rate in group E is highest under the respective condition. Statistical significance was observed for group D during post prandial.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008515130A JP2008545766A (en) | 2005-06-07 | 2006-06-07 | (-)-New use of epigallocatechin gallate |
EP06743119A EP1888173A2 (en) | 2005-06-07 | 2006-06-07 | Novel use of (-)-epigallocatechin gallate |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05012235 | 2005-06-07 | ||
EP05012235.7 | 2005-06-07 | ||
EP05025412 | 2005-11-22 | ||
EP05025412.7 | 2005-11-22 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006131326A2 true WO2006131326A2 (en) | 2006-12-14 |
WO2006131326A3 WO2006131326A3 (en) | 2007-07-19 |
WO2006131326B1 WO2006131326B1 (en) | 2007-11-01 |
Family
ID=36950973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/005410 WO2006131326A2 (en) | 2005-06-07 | 2006-06-07 | Novel use of (-)-epigallocatechin gallate |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1888173A2 (en) |
JP (1) | JP2008545766A (en) |
KR (1) | KR20080020617A (en) |
WO (1) | WO2006131326A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008092572A1 (en) * | 2007-02-01 | 2008-08-07 | Dsm Ip Assets B.V. | Sauce containing (-)-epiqallocatechin gallate |
WO2008092573A1 (en) * | 2007-02-01 | 2008-08-07 | Dsm Ip Assets B.V. | Novel use of (-)-epigallocatechin gallate |
WO2009015996A2 (en) * | 2007-08-02 | 2009-02-05 | Nestec S.A. | Reduction of oxidative stress damage during or after exercise |
WO2009046964A1 (en) * | 2007-10-10 | 2009-04-16 | Dsm Ip Assets B.V. | Feed composition for companion animals |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1077211A2 (en) * | 1999-08-16 | 2001-02-21 | F. Hoffmann-La Roche Ag | Process for the production of epigallocatechin gallate |
WO2004017766A1 (en) * | 2002-08-23 | 2004-03-04 | Dsm Ip Assets B.V. | Novel nutraceutical compositions comprising biotin |
WO2004037018A1 (en) * | 2002-10-23 | 2004-05-06 | Quercegen Holdings Llc | Composition for enhancing physical performance |
WO2004110175A1 (en) * | 2003-06-04 | 2004-12-23 | Nestec S.A. | Weight management beverage |
WO2005014020A1 (en) * | 2003-07-08 | 2005-02-17 | Interhealth Nutraceuticals Incorporated | Compositions incorporating high-caffeine green tea extract and related methods for promoting healthy body weight |
WO2005027661A1 (en) * | 2003-09-23 | 2005-03-31 | Dsm Ip Assets B.V. | Compositions for the treatment and prevention of diabetes mellitus |
US20050095233A1 (en) * | 2000-12-28 | 2005-05-05 | Mccleary Edward L. | Composition and method for reducing lipid storage |
WO2005115425A1 (en) * | 2004-05-28 | 2005-12-08 | Suntory Limited | Composition comprising fermented tea extract as the main component and having effect of incrasing adiponectin |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3756438B2 (en) * | 2001-03-02 | 2006-03-15 | 花王株式会社 | Container drink |
JP3756510B2 (en) * | 2001-03-02 | 2006-03-15 | 花王株式会社 | Containerized beverage for burning body fat. |
JP4324335B2 (en) * | 2001-09-07 | 2009-09-02 | 花王株式会社 | Catechin-containing beverage |
JP4494033B2 (en) * | 2003-02-10 | 2010-06-30 | 株式会社 伊藤園 | Serum cholesterol lowering agent, food and drink, and method for producing the same |
-
2006
- 2006-06-07 WO PCT/EP2006/005410 patent/WO2006131326A2/en active Application Filing
- 2006-06-07 EP EP06743119A patent/EP1888173A2/en not_active Withdrawn
- 2006-06-07 KR KR1020077028539A patent/KR20080020617A/en not_active Application Discontinuation
- 2006-06-07 JP JP2008515130A patent/JP2008545766A/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1077211A2 (en) * | 1999-08-16 | 2001-02-21 | F. Hoffmann-La Roche Ag | Process for the production of epigallocatechin gallate |
US20050095233A1 (en) * | 2000-12-28 | 2005-05-05 | Mccleary Edward L. | Composition and method for reducing lipid storage |
WO2004017766A1 (en) * | 2002-08-23 | 2004-03-04 | Dsm Ip Assets B.V. | Novel nutraceutical compositions comprising biotin |
WO2004037018A1 (en) * | 2002-10-23 | 2004-05-06 | Quercegen Holdings Llc | Composition for enhancing physical performance |
WO2004110175A1 (en) * | 2003-06-04 | 2004-12-23 | Nestec S.A. | Weight management beverage |
WO2005014020A1 (en) * | 2003-07-08 | 2005-02-17 | Interhealth Nutraceuticals Incorporated | Compositions incorporating high-caffeine green tea extract and related methods for promoting healthy body weight |
WO2005027661A1 (en) * | 2003-09-23 | 2005-03-31 | Dsm Ip Assets B.V. | Compositions for the treatment and prevention of diabetes mellitus |
WO2005115425A1 (en) * | 2004-05-28 | 2005-12-08 | Suntory Limited | Composition comprising fermented tea extract as the main component and having effect of incrasing adiponectin |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI Section Ch, Week 200308 Derwent Publications Ltd., London, GB; Class B02, AN 2003-084863 XP002350709 & JP 2002 326932 A (KAO CORP) 15 November 2002 (2002-11-15) * |
DATABASE WPI Section Ch, Week 200350 Derwent Publications Ltd., London, GB; Class B02, AN 2003-527862 XP002350707 & JP 2003 081825 A (KAO CORP) 19 March 2003 (2003-03-19) * |
DATABASE WPI Section Ch, Week 200468 Derwent Publications Ltd., London, GB; Class B03, AN 2004-693423 XP002350710 & JP 2004 262927 A (ITOEN KK) 24 September 2004 (2004-09-24) * |
DATABASE WPI Section Ch, Week 200530 Derwent Publications Ltd., London, GB; Class B04, AN 2005-289143 XP002350708 & JP 2005 095186 A (KAO CORP) 14 April 2005 (2005-04-14) * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008092572A1 (en) * | 2007-02-01 | 2008-08-07 | Dsm Ip Assets B.V. | Sauce containing (-)-epiqallocatechin gallate |
WO2008092573A1 (en) * | 2007-02-01 | 2008-08-07 | Dsm Ip Assets B.V. | Novel use of (-)-epigallocatechin gallate |
EP1961310A1 (en) * | 2007-02-01 | 2008-08-27 | DSMIP Assets B.V. | Novel use of (-) -epigallocatechin gallate |
EP1969954A1 (en) * | 2007-02-01 | 2008-09-17 | DSMIP Assets B.V. | Sauce containing (-)-epigallocatechin gallate |
JP2010517949A (en) * | 2007-02-01 | 2010-05-27 | ディーエスエム アイピー アセッツ ビー.ブイ. | (−)-New use of epigallocatechin gallate |
WO2009015996A2 (en) * | 2007-08-02 | 2009-02-05 | Nestec S.A. | Reduction of oxidative stress damage during or after exercise |
WO2009015996A3 (en) * | 2007-08-02 | 2009-04-02 | Nestec Sa | Reduction of oxidative stress damage during or after exercise |
WO2009046964A1 (en) * | 2007-10-10 | 2009-04-16 | Dsm Ip Assets B.V. | Feed composition for companion animals |
Also Published As
Publication number | Publication date |
---|---|
JP2008545766A (en) | 2008-12-18 |
KR20080020617A (en) | 2008-03-05 |
WO2006131326B1 (en) | 2007-11-01 |
EP1888173A2 (en) | 2008-02-20 |
WO2006131326A3 (en) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6830359B2 (en) | Nutritional composition | |
CN104918610B (en) | For strengthening the composition and method of energetic supersession | |
CN106456997A (en) | Compositions and methods for the reduction or prevention of hepatic steatosis | |
JP5121308B2 (en) | Composition for preventing, improving or treating metabolic syndrome | |
US20120010285A1 (en) | Agent for promoting energy consumption | |
KR101860165B1 (en) | Coffee extracts as ingredients of foods, drugs, cosmetics, dietary supplements, and biologics | |
Yonei et al. | Effects on the human body of a dietary supplement containing L-carnitine and Garcinia cambogia extract: a study using double-blind tests | |
US8829057B2 (en) | AMPK activating agent | |
EP2532351B1 (en) | Agent for improving motility function | |
Cho et al. | Effect of loquat leaf extract on muscle strength, muscle mass, and muscle function in healthy adults: a randomized, double‐blinded, and placebo‐controlled trial | |
KR20240057401A (en) | Paraxanthin-based caffeine substitute composition and method of use thereof in slow caffeine metabolizers | |
CN103857404A (en) | Agent for improving quality of sleep | |
WO2018117041A1 (en) | Lipid metabolism-promoting composition including isoxanthohumol | |
JP2006131512A (en) | Composition for accelerating secretion of adiponectin and food and drink containing the composition | |
WO2006131326A2 (en) | Novel use of (-)-epigallocatechin gallate | |
JP5281268B2 (en) | Strength improver | |
CN107624068A (en) | The application method of composition and such composition comprising cinnamic acid and zinc | |
Park et al. | Efficacy and safety of Sinetrol-XPur on weight and body fat reduction in overweight or obese adults: A 12-week, randomized, double-blind, parallel, placebo-controlled trial | |
CN101370555A (en) | Novel use of (-)-epigallocatechin gallate | |
Kumar et al. | Effect of coffee on blood pressure and electrocardiographic changes in young and elderly healthy subjects | |
JP6417120B2 (en) | Oral UV resistance improver | |
KR101695299B1 (en) | Composition for preventing or treating obesity or hyperlipidemia containing Piper longum extract, soy extract containing isoflavon and L-carnitin | |
EP3834629A1 (en) | Composition and method for suppressing increase in blood glucose level | |
JP2023545272A (en) | O-acetylserine for use in the prevention and treatment of glucose intolerance and related diseases | |
POLYPHARMACY | DIETARY EPICATECHIN IMPROVES SURVIVAL AND SKELETAL MUSCLE FUNCTION VIA MULTIPLE MECHANISMS IN AGED MICE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680020337.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006743119 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077028539 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008515130 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10171/DELNP/2007 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006743119 Country of ref document: EP |